Drug and vaccine authorizations for COVID-19: Overview

Health Canada scientific reviewers evaluate data to assess the potential benefits and risks of a drug or vaccine. They also review the information that will be provided to health care practitioners and consumers about the product. After the review, we may authorize the drug or vaccine for sale in Canada only if the benefits of the product outweigh the potential risks.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 22:03 (TU)
Créé le avril 17, 2026, 22:03 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2020-09-13 00:00:00
open_canada_keywords {"fr": ["COVID-19", "pandémie", "autorisation de médicament et de vaccin", "autoriser la vente du médicaments ou du vaccin", "avantages et risques potentiels d'un médicament ou d'un vaccin", "professionnels de la santé et consommateurs", "avantages", "risques potentiels"], "en": ["COVID-19", "pandemic", "drug and vaccine authorizations", "authorize the drug or vaccine for sale", "potential benefits and risks of a drug or vaccine", "health care practitioners and consumers", "benefits of the product", "potential risks"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Autorisation de médicament et de vaccin contre la COVID-19 : Aperçu
update_frequency as_needed